查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006212

蛋白酪氨酸激酶抑制剂市场：2026-2032年全球市场预测（依适应症、标靶、代数、给药途径及分销通路划分）

Tyrosine Kinase Inhibitors Market by Indication, Target, Generation, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，蛋白酪氨酸激酶抑制剂市场价值将达到 682.1 亿美元，到 2026 年将成长至 733.6 亿美元，到 2032 年将达到 1,117.5 亿美元，复合年增长率为 7.30%。

主要市场统计数据
基准年 2025 682.1亿美元
预计年份：2026年 733.6亿美元
预测年份 2032 1117.5亿美元
复合年增长率 (%) 7.30%

全面概述蛋白酪氨酸激酶抑制剂如何从标靶治疗概念发展成为现代肿瘤学中临床和商业性的重点。

蛋白酪氨酸激酶抑制剂透过将分子层面的见解转化为标靶治疗，从而带来切实的临床获益，彻底改变了我们治疗肿瘤的方式。在过去的二十年中，随着生物标记识别技术的进步和对抗药性机制理解的加深，这些药物已从实验性治疗发展成为多种肿瘤类型的核心疗法。儘管随着新一代抑制剂的不断问世和患者选择标准的不断完善，临床疗效持续改善，但竞争格局也变得更加复杂，因为如今药物的差异化取决于耐受性、抗药性光谱以及联合治疗的潜力。

科学进步、适应性临床试验设计、支付方期望和供应链韧性如何重新定义蛋白酪氨酸激酶抑制剂生态系统。

蛋白酪氨酸激酶抑制剂领域正经历一系列变革，这些变革正在重新定义产品的开发、定位和获取途径。科学进步加速了新型有效标靶的发现，并不断催生出旨在克服标靶抗药性和中枢神经系统穿透性等挑战的新一代药物。同时，临床开发也变得更加迭代。篮式试验和伞式试验、适应性通讯协定以及真实世界数据（RWE）的整合正在缩短假设检验週期，并促成更动态的「启动/停止」决策。

评估 2025 年美国关税变化如何重塑癌症药物生产中的供应链韧性、筹资策略和成本管理。

美国提案于2025年实施的关税措施对全球抗癌药物生产供应链产生了复杂的影响，尤其对蛋白酪氨酸激酶抑制剂、活性药物成分和关键成分的供应造成了衝击。跨境采购中间体和成品的製造商面临潜在的成本压力，这种压力会波及采购、契约製造和分销等各个环节。为了应对这些压力，许多公司正在探索供应商地域多元化、更多地利用本地或近岸製造伙伴关係以及重新谈判长期供应合同，以维持盈利能力和供应的连续性。

详细的細項分析解释了适应症、分子标靶、世代、给药途径和分销管道如何相互交织并塑造产品策略。

细分市场洞察揭示了治疗重点、基于机制的标靶和给药策略的交汇点，从而影响临床开发和商业化策略。基于适应症，本研究对乳癌、慢性骨髓性白血病、非小细胞肺癌和肾细胞癌的市场进行了分析。慢性骨髓性白血病进一步细分为第一线、第二线和第三线治疗方案。同样，非小细胞肺癌也细分为第一线、第二线和三线治疗方案。这些基于适应症的区分至关重要，因为固体癌和骨髓恶性肿瘤在临床终点预期、竞争格局和标准治疗顺序方面存在显着差异，从而影响试验设计和适应症策略。

区域监管差异、支付方趋势和当地生产重点，使得蛋白酪氨酸激酶抑制剂的开发和取得需要采取差异化的全球策略。

区域趋势对蛋白酪氨酸激酶抑制剂的临床开发优先顺序、监管合作和商业化路径有显着影响，因此，制定有效的全球策略必须具备区域观点。在美洲，儘管监管机构维持着快速核准机制，但支付方越来越要求提供强有力的卫生经济学证据和结果数据以支持报销，这推动了早期卫生技术评估的开展和真实世界数据（RWE）项目的扩展。在欧洲、中东和非洲（EMEA），监管环境的异质性和支付方能力的差异，使得个人化的市场进入、区域伙伴关係和灵活的定价策略成为必要，以促进跨多个司法管辖区的报销和竞标流程。在亚太地区，快速的病患招募能力、新兴的国家创新生态系统和多样化的法规结构，既为快速商业化提供了机会，也带来了复杂的在地化调整的必要性。在生产和技术转移能够带来竞争优势的地区，这一趋势尤其明显。

策略竞争行为和伙伴关係模式推动标靶癌症疗法的产品差异化、产品线优先排序和商业化效率。

蛋白酪氨酸激酶抑制剂领域製药和生物技术公司的竞争行为反映出对持续创新和优化商业性执行的高度重视。主要企业日益优先研发旨在克服抗药性突变和提高耐受性的下一代分子，而中型和新兴企业则倾向于瞄准特定适应症或基于生物标记定义的患者群体，以建立稳固的市场地位。创新者与合约开发组织（CDO）之间的合作仍然是加速规模化生产和维持生产柔软性的关键，而授权协议仍然是确保区域商业化和市场准入的有效途径。

为肿瘤领域的产业领导者提供可操作的策略步骤，以加强产品组合重点、供应链韧性、证据产生和商业化准备。

在蛋白酪氨酸激酶抑制剂领域不断演变的格局中，产业领导者应采取一系列切实有效的措施，将科学差异化与营运准备相结合，以确保临床和商业性效益。首先，为最大限度降低后期重新定位的风险，应优先考虑将新一代分子设计与明确的临床定位和抗药性管理策略相结合的产品组合决策。其次，透过原料药(API) 和组件来源多元化、尽可能投资双重采购以及扩大近岸生产选择，增强供应链韧性并降低关税和地缘政治风险。第三，将价值验证儘早纳入研发计划，透过将卫生经济学终点、真实世界数据 (RWD) 收集和患者报告结局 (PRO) 纳入註册和上市后监测，为与支付方的谈判和基于价值的合约提供支援。

一种透明且可重复的调查方法，结合了初步访谈、文献整合、专利和临床研发管线分析以及基于情境的洞察三角验证。

本分析的调查方法结合了定性和定量方法，将临床、监管和商业资讯整合为可操作的见解。主要研究包括对临床研究人员、监管专家、支付方顾问和供应链高管进行结构化访谈，以获取关于试验设计偏好、报销预期和营运限制的第一手观点。次要研究则仔细审查了同行评审文献、监管指导文件、临床试验註册信息和上市公司资讯披露，以全面检验发展趋势和过往监管先例。专利格局分析和临床研发管线图谱用于评估基于机制的创新密度和竞争情况。

策略重点整合表明，肿瘤学领域的长期成功取决于科学创新、营运韧性和证据产生的结合。

总之，蛋白酪氨酸激酶抑制剂仍然是肿瘤治疗领域的重要药物类别，持续的创新既推动了新的临床应用，也增加了策略复杂性。分子标靶疗法的进步，以及对适应性试验设计和真实世界临床结果的重视，正在重塑药物研发模式和商业性预期。贸易政策的变化和供应链的脆弱性等外部压力，迫使製药公司重新思考筹资策略，并将韧性融入其商业模式。同时，区域监管差异和不断变化的支付方需求，也要求制定个人化的准入策略，以平衡全球证据的累积和在地化需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：蛋白酪氨酸激酶抑制剂市场：依适应症划分

  • 乳癌
  • 慢性骨髓性白血病
    • 第一选择
    • 第二行
    • 第三行
  • 非小细胞肺癌
    • 第一选择
    • 第二行
    • 第三行
  • 肾臟细胞癌

第九章：以标靶分類的蛋白酪氨酸激酶抑制剂市场

  • ALK
  • Bcr-Abl
    • 第一代
    • 第二代
    • 第三代
  • EGFR
    • 第一代
    • 第二代
    • 第三代
  • VEGFR

第十章：蛋白酪氨酸激酶抑制剂市场（按代划分）

  • 第一代
  • 第二代
  • 第三代

第十一章：蛋白酪氨酸激酶抑制剂市场：依给药途径划分

  • 静脉
  • 口服

第十二章：蛋白酪氨酸激酶抑制剂市场：依通路划分

  • 医院药房
  • 零售药房

第十三章：蛋白酪氨酸激酶抑制剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：蛋白酪氨酸激酶抑制剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：蛋白酪氨酸激酶抑制剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国蛋白酪氨酸激酶抑制剂市场

第十七章：中国蛋白酪氨酸激酶抑制剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B168537796FC

The Tyrosine Kinase Inhibitors Market was valued at USD 68.21 billion in 2025 and is projected to grow to USD 73.36 billion in 2026, with a CAGR of 7.30%, reaching USD 111.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 68.21 billion
Estimated Year [2026] USD 73.36 billion
Forecast Year [2032] USD 111.75 billion
CAGR (%) 7.30%

Comprehensive overview of how tyrosine kinase inhibitors transitioned from targeted concepts to integrated clinical and commercial priorities in modern oncology

Tyrosine kinase inhibitors have reshaped the therapeutic landscape for oncology by converting molecular insights into targeted therapies that deliver tangible clinical benefit. Over the past two decades, these agents have moved from experimental therapies to cornerstone treatments in multiple tumor types, driven by increasingly precise biomarker identification and enhanced understanding of resistance mechanisms. The introduction of successive generations of inhibitors and the refinement of patient selection criteria have progressively improved clinical outcomes while simultaneously complicating competitive dynamics as differentiation now rests on tolerability, resistance profiles, and combination potential.

Today's strategic conversations emphasize not only molecule-level efficacy but also durable development pathways that integrate companion diagnostics, adaptive trial designs, and payer-driven evidence requirements. Regulatory pathways continue to evolve alongside accelerated approvals and conditional pathways, prompting developers to balance speed with the need for confirmatory evidence. As a result, stakeholders must align clinical development plans, commercial access strategies, and manufacturing capabilities to ensure that scientific advantages convert into patient access and commercial viability. Transitioning from proof-of-concept to sustainable product franchises requires cohesive cross-functional planning and nimble responses to evolving clinical and regulatory data.

How scientific advances, adaptive clinical designs, payer expectations, and supply chain resilience are collectively redefining the tyrosine kinase inhibitor ecosystem

The landscape for tyrosine kinase inhibitors is undergoing a set of transformative shifts that are redefining how products are developed, positioned, and accessed. Scientific advances have accelerated the identification of novel actionable targets and led to the proliferation of next-generation agents designed to overcome on-target resistance and central nervous system penetration challenges. Concurrently, clinical development is becoming more iterative: basket and umbrella trials, adaptive protocols, and real-world evidence integration are shortening hypothesis cycles and enabling more dynamic go/no-go decisions.

Commercially, differentiation is migrating from single-agent efficacy to a broader value proposition that includes tolerability, sequencing strategies, and combination potential with immunotherapies and other targeted agents. Payers and health systems are increasingly focused on total cost of care and longitudinal outcomes, prompting manufacturers to develop more robust evidence packages and outcomes-based agreements. Manufacturing and supply chain resilience have emerged as strategic priorities in response to geopolitical tensions and regulatory scrutiny, while digital tools and decentralized trial elements are improving patient recruitment and retention. These converging trends require a new playbook that combines deep scientific rigor with commercial agility and supply chain foresight.

Assessment of how 2025 tariff changes in the United States are reshaping supply chain resilience, sourcing strategies, and cost management for oncology drug production

Proposed and implemented tariff measures in the United States for 2025 have introduced a complex set of implications for the global supply chains underpinning oncology drug production, with particular relevance for tyrosine kinase inhibitor supply, active pharmaceutical ingredients, and key componentry. Manufacturers that source intermediates or finished dosage forms across borders face potential cost pressures that can cascade through procurement, contract manufacturing, and distribution relationships. In response, many companies are evaluating the geographic diversification of suppliers, increasing use of local or near-shore manufacturing partnerships, and renegotiation of long-term supply agreements to preserve margin and continuity of supply.

Beyond immediate cost considerations, tariffs influence strategic decisions around inventory policies, lead times, and regulatory filings tied to manufacturing sites. Firms are reassessing the resilience of single-source dependencies and accelerating investments in dual-sourcing and strategic stockpiles where feasible. Moreover, tariff-driven price pressures can intensify payer scrutiny and amplify the need for stronger pharmacoeconomic evidence to justify premium pricing for next-generation agents. In parallel, trade policy uncertainty is prompting closer collaboration between commercial, regulatory, and manufacturing teams to model scenarios, mitigate disruption risk, and align contingency plans that maintain patient access despite shifting cross-border cost structures.

In-depth segmentation analysis explaining how indication, molecular target, generation, administration route, and distribution channels converge to shape product strategy

Segmentation insights illuminate where therapeutic focus, mechanistic targeting, and delivery strategies intersect to shape clinical development and commercialization approaches. Based on Indication, market is studied across Breast Cancer, Chronic Myeloid Leukemia, Non Small Cell Lung Cancer, and Renal Cell Carcinoma. The Chronic Myeloid Leukemia is further studied across First Line, Second Line, and Third Line. The Non Small Cell Lung Cancer is further studied across First Line, Second Line, and Third Line. These indication-focused distinctions are critical because clinical endpoint expectations, competitive backdrops, and standard-of-care sequences differ markedly between solid tumors and hematologic malignancies, influencing trial design and label strategy.

Based on Target, market is studied across Alk, Bcr-Abl, EGFR, and Vegfr. The Bcr-Abl is further studied across First Generation, Second Generation, and Third Generation. The EGFR is further studied across First Generation, Second Generation, and Third Generation. Target-specific segmentation highlights how molecular selectivity and resistance profiles drive differentiation and clinical positioning, while generational distinctions reflect evolutionary design efforts to improve potency and evade resistance. Based on Generation, market is studied across First Generation, Second Generation, and Third Generation; this lens helps clarify how incremental innovations shift tolerability and sequencing narratives. Based on Route Of Administration, market is studied across Intravenous and Oral, signaling divergent development, manufacturing, and adherence considerations that affect commercial uptake. Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies, indicating where stakeholder engagement, channel economics, and patient access strategies will materially differ. Together, these segmentation dimensions provide an analytical scaffold to evaluate clinical opportunity, operational requirements, and commercial tactics across heterogeneous therapeutic contexts.

How regional regulatory diversity, payer dynamics, and local manufacturing priorities require differentiated global strategies for tyrosine kinase inhibitor development and access

Regional dynamics materially shape clinical development priorities, regulatory interactions, and commercialization pathways for tyrosine kinase inhibitors, and a region-sensitive perspective is essential to effective global strategy. In the Americas, regulatory agencies maintain accelerated approval mechanisms while payers increasingly demand robust health economic evidence and outcomes data to support reimbursement, driving early heath technology assessment engagement and expanded real-world evidence programs. In Europe, Middle East & Africa, regulatory heterogeneity and variable payer capabilities require tailored market access approaches, regional partnerships, and flexible pricing strategies to navigate reimbursement and tender processes across multiple jurisdictions. In Asia-Pacific, rapid enrollment capacities, rising domestic innovation ecosystems, and diverse regulatory frameworks create both swift commercial opportunities and complex local adaptation needs, particularly where manufacturing localization and technology transfer can support competitive positioning.

Across all regions, cross-border clinical collaboration and harmonized data generation approaches can streamline evidence development while region-specific commercialization playbooks must address distinct stakeholder landscapes, patient pathways, and distribution structures. Regulatory timelines, patient population characteristics, and healthcare financing models vary significantly, and therefore global programs must incorporate modular launch strategies that allow for concurrent but differentiated market entry plans. Adapting to regional nuances in clinical expectations and payer decision frameworks will be critical to maximizing the clinical and commercial impact of new tyrosine kinase inhibitor entrants.

Strategic competitive behaviors and partnership models that are driving product differentiation, pipeline prioritization, and commercialization effectiveness in targeted oncology therapies

Competitive behavior across pharmaceutical and biotech companies in the tyrosine kinase inhibitor space reflects an intense focus on sustaining innovation while optimizing commercial execution. Leading firms are increasingly prioritizing next-generation molecules designed to overcome resistance mutations and improve tolerability, while mid-sized and emerging companies often pursue niche indications or biomarker-defined populations to create defensible footholds. Partnerships between innovators and contract development organizations remain central to accelerating scale-up and maintaining flexibility in manufacturing, and licensing transactions continue to be a pragmatic route for regional commercialization and access.

Strategic pipelines emphasize complementary modalities such as antibody-drug conjugates, combination regimens with immunotherapies, and efforts to pair small-molecule inhibitors with precision diagnostic platforms. Business development activity focuses on securing late-stage assets or platform technologies that can be integrated into multi-line treatment sequences. At the same time, companies face increasing pressure to demonstrate value beyond clinical endpoints, necessitating investments in health economics teams, real-world evidence generation, and payer engagement capabilities. Operationally, organizations that invest early in scalable manufacturing, robust pharmacovigilance, and cross-functional launch readiness are better positioned to convert clinical differentiation into durable commercial performance.

Actionable strategic steps for industry leaders to strengthen portfolio focus, supply chain resilience, evidence generation, and commercialization readiness in oncology

To capture clinical and commercial upside in the evolving tyrosine kinase inhibitor environment, industry leaders should pursue a set of pragmatic, high-impact actions that align scientific differentiation with operational readiness. First, prioritize portfolio decisions that couple next-generation molecular design with clearly articulated clinical positioning and resistance management strategies to minimize late-stage repositioning risk. Second, fortify supply chain resilience by diversifying API and component sourcing, investing in dual-sourcing where feasible, and expanding near-shore manufacturing options to mitigate tariff and geopolitical exposure. Third, integrate value demonstration into development plans early by embedding health economic endpoints, real-world data collection, and patient-reported outcomes into registrational and post-marketing studies to support payer discussions and value-based contracting.

Additionally, embrace flexible trial methodologies such as adaptive designs and decentralized elements to accelerate enrollment and gather broader patient data while reducing cost and time to insight. Strengthen commercialization readiness through early stakeholder mapping, channel optimization for hospital and retail pharmacy pathways, and tailored regional launch plans that reflect local regulatory and payer requirements. Finally, pursue targeted collaborations-whether through licensing, co-development, or commercial partnerships-to extend geographic reach, accelerate scale-up, and combine complementary scientific assets. These actions collectively reduce execution risk and enable organizations to translate molecular advances into sustainable therapeutic impact.

Transparent and reproducible research methodology combining primary interviews, literature synthesis, patent and clinical pipeline analysis, and scenario-based triangulation of insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to synthesize clinical, regulatory, and commercial intelligence into an actionable view. Primary research included structured interviews with clinical investigators, regulatory specialists, payer advisors, and supply chain executives to capture first-hand perspectives on trial design preferences, reimbursement expectations, and operational constraints. Secondary research reviewed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to triangulate development trends and historical regulatory precedents. Patent landscaping and clinical pipeline mapping informed assessments of mechanistic innovation and competitive density.

Data synthesis applied a triangulation approach to validate insights across independent sources, and scenario analysis was used to explore the operational implications of supply chain and policy shocks. Limitations are acknowledged, including the evolving nature of clinical data and policy changes that may shift the competitive landscape; accordingly, recommendations emphasize resilient, adaptable strategies rather than single-point predictions. The methodology prioritized reproducibility and transparency in assumptions, and where expert opinion supplemented public data, that synthesis was clearly flagged and cross-checked against available empirical evidence to ensure robustness.

Synthesis of strategic priorities showing how scientific innovation combined with operational resilience and evidence generation will determine long-term success in oncology

In conclusion, tyrosine kinase inhibitors remain a pivotal class of oncology therapeutics with continuous innovation driving both new clinical possibilities and heightened strategic complexity. Advances in molecular targeting, coupled with adaptive trial designs and an emphasis on real-world outcomes, are reshaping development paradigms and commercial expectations. External pressures such as trade policy shifts and supply chain vulnerabilities are compelling manufacturers to rethink sourcing strategies and to integrate resilience into their operational models. At the same time, regional regulatory divergence and evolving payer demands necessitate tailored access strategies that reconcile global evidence generation with local requirements.

Ultimately, organizations that align scientific differentiation with rigorous evidence generation, robust manufacturing planning, and region-specific commercialization readiness will be best positioned to convert therapeutic promise into clinical impact and sustainable business performance. Collaboration across clinical, regulatory, manufacturing, and commercial functions is essential, as is a willingness to adopt flexible development pathways and innovative contracting approaches that reflect the realities of modern oncology care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tyrosine Kinase Inhibitors Market, by Indication

  • 8.1. Breast Cancer
  • 8.2. Chronic Myeloid Leukemia
    • 8.2.1. First Line
    • 8.2.2. Second Line
    • 8.2.3. Third Line
  • 8.3. Non Small Cell Lung Cancer
    • 8.3.1. First Line
    • 8.3.2. Second Line
    • 8.3.3. Third Line
  • 8.4. Renal Cell Carcinoma

9. Tyrosine Kinase Inhibitors Market, by Target

  • 9.1. Alk
  • 9.2. Bcr-Abl
    • 9.2.1. First Generation
    • 9.2.2. Second Generation
    • 9.2.3. Third Generation
  • 9.3. EGFR
    • 9.3.1. First Generation
    • 9.3.2. Second Generation
    • 9.3.3. Third Generation
  • 9.4. Vegfr

10. Tyrosine Kinase Inhibitors Market, by Generation

  • 10.1. First Generation
  • 10.2. Second Generation
  • 10.3. Third Generation

11. Tyrosine Kinase Inhibitors Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Tyrosine Kinase Inhibitors Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies

13. Tyrosine Kinase Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Tyrosine Kinase Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tyrosine Kinase Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Tyrosine Kinase Inhibitors Market

17. China Tyrosine Kinase Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Astellas Pharma Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Blueprint Medicines Corporation
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Eli Lilly and Company
  • 18.13. Exelixis, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Incyte Corporation
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Pfizer Inc.
  • 18.19. Rigel Pharmaceuticals, Inc.
  • 18.20. Roche Holding AG
  • 18.21. Sanofi S.A.
  • 18.22. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 187. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 189. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 191. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 217. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 219. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 221. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 222. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 227. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 228. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 229. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 231. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)